Clinical Trials Search
A Phase II, Multicenter, Randomized, Two-Arm Study Of Capmatinib (INC280, An Oral MET Inhibitor) And Spartalizumab (PDR001, A PD-1 Inhibitor) Combination Therapy Versus Docetaxel In Pretreated Adult Patients With EGFR Wild-Type, ALK Rearrangement Negative Locally Advanced/Metastatic Non-Small Cell Lung Cancer
Part 1: Run-in To assess the safety and tolerability of the capmatinib and spartalizumab combination. Part 2: Randomized To assess the overall survival of the combination of capmatinib and spartalizumab in comparison to docetaxel Part 2 Randomized part: To assess objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), duration of response (DOR) and time to response (TTR) based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors). To assess the incidence and severity of adverse events (AEs) and serious adverse events (SAEs).